Skip to main content

Advertisement

SpringerLink
Log in

Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background and Aims

The role of infliximab in the treatment of patients with ulcerative colitis (UC) in Asia is still unclear. The aim of this study was to evaluate the clinical outcomes of infliximab therapy in Korean UC patients, including efficacy and predictors of response.

Methods

Patients who received infliximab induction therapy for moderate to severe UC at Asan Medical Center were retrospectively analyzed. The demographic characteristics of these patients and their clinical outcomes following infliximab therapy were evaluated.

Results

Of the 89 UC patients receiving infliximab induction therapy, 53 (59.6 %) were steroid-refractory and 36 (40.4 %) were steroid-dependent. At the initiation of infliximab, the median Mayo score was 9 (range 7–12). After the induction therapy of infliximab, 59 patients (66.3 %) demonstrated a clinical response at week 8, of which 29 (32.6 %) were determined to be in clinical remission. A colectomy was performed within 1 year after infliximab initiation in 11 (36.7 %) of 30 patients who displayed no clinical response to infliximab therapy, but in none of the 59 patients who showed a response to this drug (p < 0.001). Multivariate regression analysis identified severe disease (Mayo score ≥ 11) at the initiation of infliximab (p = 0.007) and history of cytomegalovirus colitis within 3 months prior to infliximab treatment (p = 0.001) as independent positive predictors of nonresponse to infliximab.

Conclusions

The efficacy of infliximab in Korean UC patients seems to be similar to that of previously published Western reports. Severe disease and a history of cytomegalovirus colitis are predictors of a nonresponse to infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.

    Article  PubMed  CAS  Google Scholar 

  2. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444–1451.

    PubMed  CAS  Google Scholar 

  3. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005; 1:CD004277.

    Google Scholar 

  4. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443–1453.

    Article  PubMed  CAS  Google Scholar 

  5. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.

    Article  PubMed  CAS  Google Scholar 

  6. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805–1811.

    Article  PubMed  Google Scholar 

  7. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97:2577–2584.

    Article  PubMed  CAS  Google Scholar 

  8. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–128.

    Article  PubMed  Google Scholar 

  9. Jurgens M, Laubender RP, Hartl F, et al. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811–1819.

    Article  PubMed  Google Scholar 

  10. Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219–225.

    Article  PubMed  Google Scholar 

  11. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411–419.

    Article  PubMed  CAS  Google Scholar 

  12. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.

    Article  PubMed  CAS  Google Scholar 

  13. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104:2100–2109.

    Article  PubMed  Google Scholar 

  14. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008;103:3167–3182.

    Article  PubMed  Google Scholar 

  15. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008;14:542–549.

    Article  PubMed  Google Scholar 

  16. Garland CF, Lilienfeld AM, Mendeloff AI, Markowitz JA, Terrell KB, Garland FC. Incidence rates of ulcerative colitis and Crohn’s disease in fifteen areas of the United States. Gastroenterology. 1981;81:1115–1124.

    PubMed  CAS  Google Scholar 

  17. Binder V, Both H, Hansen PK, Hendriksen C, Kreiner S, Torp-Pedersen K. Incidence and prevalence of ulcerative colitis and Crohn’s disease in the County of Copenhagen, 1962 to 1978. Gastroenterology. 1982;83:563–568.

    PubMed  CAS  Google Scholar 

  18. Tysk C, Jarnerot G. Ulcerative proctocolitis in Orebro, Sweden. A retrospective epidemiologic study, 1963-1987. Scand J Gastroenterol. 1992;27:945–950.

    Article  PubMed  CAS  Google Scholar 

  19. Yang SK, Hong WS, Min YI, et al. Incidence and prevalence of ulcerative colitis in the Songpa-Kangdong District, Seoul, Korea, 1986-1997. J Gastroenterol Hepatol. 2000;15:1037–1042.

    Article  PubMed  CAS  Google Scholar 

  20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.

    Article  PubMed  CAS  Google Scholar 

  21. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.

    Article  PubMed  Google Scholar 

  22. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47–91.

    Article  PubMed  CAS  Google Scholar 

  23. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.

    Article  PubMed  CAS  Google Scholar 

  24. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885.

    Article  PubMed  CAS  Google Scholar 

  25. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4 + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–1270.

    PubMed  CAS  Google Scholar 

  26. Yang SK, Jung Y, Hong M, et al. No association between TNFSF15 and IL23R with ulcerative colitis in Koreans. J Hum Genet. 2011;56:200–204.

    Article  PubMed  CAS  Google Scholar 

  27. Park SH, Kim YM, Yang SK, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis. 2007;13:278–283.

    Article  PubMed  Google Scholar 

  28. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–440.

    Article  PubMed  Google Scholar 

  29. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.

    PubMed  CAS  Google Scholar 

  30. Farmer RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137–1146.

    Article  PubMed  CAS  Google Scholar 

  31. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617–2625.

    Article  PubMed  CAS  Google Scholar 

  32. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.

    Article  PubMed  CAS  Google Scholar 

  33. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis. 2010;16:1620–1627.

    Article  PubMed  Google Scholar 

  34. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20:202–213.

    Article  PubMed  Google Scholar 

  35. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol. 2012;46:51–56.

    Article  PubMed  CAS  Google Scholar 

  36. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001–2008.

    Article  PubMed  CAS  Google Scholar 

  37. Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007;102:331–337.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant of the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A120176). Suk-Kyun Yang has received a research grant from Janssen Korea Ltd.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea

    Sang Hyoung Park, Suk-Kyun Yang, Soo-Kyung Park, Jong Wook Kim, Hyo Jeong Lee, Dong-Hoon Yang, Kee Wook Jung, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung & Jin-Ho Kim

  2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Seung-Mo Hong

  3. Division of Gastroenterology, Department of Internal Medicine, Inje University Ilsan Paik Hospital, 2240 Daehwa-dong, Ilsanseo-gu, Gyeonggi-do, Goyang-si, 411-706, Korea

    Jong Wook Kim

Authors
  1. Sang Hyoung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suk-Kyun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung-Mo Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Soo-Kyung Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jong Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hyo Jeong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dong-Hoon Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kee Wook Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kyung-Jo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Byong Duk Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jeong-Sik Byeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Seung-Jae Myung
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jin-Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Suk-Kyun Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, S.H., Yang, SK., Hong, SM. et al. Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis. Dig Dis Sci 58, 3592–3599 (2013). https://doi.org/10.1007/s10620-013-2828-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-013-2828-1

Keywords

Search

Navigation